Zobrazeno 1 - 10
of 71
pro vyhledávání: ''
Publikováno v:
BMC Cancer
BMC Cancer, Vol 8, Iss 1, p 153 (2008)
BMC Cancer, Vol 8, Iss 1, p 153 (2008)
Background A number of protein markers have been investigated as prognostic adjuncts in breast cancer but their translation into clinical practice has been impeded by a lack of appropriate validation. Recently, we showed that BCL2 protein expression
Publikováno v:
BMC Cancer
Lipegfilgrastim is a novel glyco-pegylated granulocyte-colony stimulating factor in development for neutropenia prophylaxis in cancer patients receiving chemotherapy. This phase III, double-blind, randomized, active-controlled, noninferiority trial c
Autor:
Claire Josse, Vincent Bours, Pierre Frères, Guy Jerusalem, Bouchra Boujemla, Stephane Wenric, Karin Segers, Raphaël Marée, Joëlle Collignon, Meriem Boukerroucha, Sonia ElGuendi
Publikováno v:
BMC Cancer
Background The BRCA1 gene plays a key role in triple negative breast cancers (TNBCs), in which its expression can be lost by multiple mechanisms: germinal mutation followed by deletion of the second allele; negative regulation by promoter methylation
Autor:
Jan G. Hengstler, Marco Johannes Battista, D. Boehm, Susanne Gebhard, Antje Lebrecht, Marcus Schmidt, Christine Solbach, W. Siggelkow, Heinz Koelbl, Cristina Cadenas, Rosemarie Marchan, Birte Hellwig, Jörg Rahnenführer, Isabel Sicking, M. Gehrmann
Publikováno v:
BMC Cancer, Vol 12, Iss 1, p 562 (2012)
BMC Cancer
BMC Cancer
Background Inhibitors targeting the cell cycle-regulated aurora kinase A (AURKA) are currently being developed. Here, we examine the prognostic impact of AURKA in node-negative breast cancer patients without adjuvant systemic therapy (n = 766). Metho
Autor:
Birgitte Bruun Rasmussen, Anne Katrine Duun-Henriksen, Sarah Larsen, Anne Vibeke Lænkholm, Christina Westmose Yde, Martin Bak, Anne E. Lykkesfeldt, Tove Kirkegaard
Publikováno v:
Larsen, S L, Yde, C W, Laenkholm, A-V, Rasmussen, B B, Duun-Henriksen, A K, Bak, M, Lykkesfeldt, A E & Kirkegaard, T 2015, ' Aurora kinase B is important for antiestrogen resistant cell growth and a potential biomarker for tamoxifen resistant breast cancer ', B M C Cancer, vol. 15, 239 . https://doi.org/10.1186/s12885-015-1210-4
BMC Cancer
BMC Cancer
BACKGROUND: Resistance to antiestrogen therapy is a major clinical challenge in the treatment of estrogen receptor α (ER)-positive breast cancer. The aim of the study was to explore the growth promoting pathways of antiestrogen resistant breast canc
Autor:
Christian F. Singer, Dietmar Pils, Dan Tong, Andrea Wolf, Margaretha Rudas, Gerda Hofstetter, Ingrid Schiebel, Nicole Concin, Georg Heinze, Robert Zeillinger
Publikováno v:
BMC Cancer, Vol 10, Iss 1, p 682 (2010)
BMC Cancer
BMC Cancer
Background Gene expression of peripheral myelin protein 22 (PMP22) and the epithelial membrane proteins (EMPs) was found to be differentially expressed in invasive and non-invasive breast cell lines in a previous study. We want to evaluate the progno
Autor:
Barbara Perić, Radan Dzodic, Rok Petric, Gasper Pilko, Hana Besic, Jan Zmuc, Nikola Besic, Andraz Perhavec
Publikováno v:
BMC Cancer
Background The population of elderly people is increasing and so is the population of breast cancer patients aged ≥80 years. The aim of our retrospective study was to identify independent prognostic factors for the duration of breast cancer-specifi
Autor:
Sandra Salvi, Pier Vitale Nuzzo, L. Zinoli, Francesco Boccardo, Simona Boccardo, Alessandra Rubagotti
Publikováno v:
BMC Cancer
Background PN is a secreted cell adhesion protein critical for carcinogenesis. In breast cancer, it is overexpressed compared to normal breast, and a few reports suggest that it has a potential role as a prognostic marker. Methods Tumour samples obta
Autor:
Kaouther Snoussi, Wijden Mahfoudh, Meriem Fekih, Ahmed Noureddine Helal, Hedi Khairi, Lotfi Chouchane, Noureddine Bouaouina
Publikováno v:
BMC Cancer, Vol 10, Iss 1, p 283 (2010)
BMC Cancer
BMC Cancer
Background Interleukin-8 (IL-8/CXCL-8) is a prototype of the ELR+CXC chemokines that play an important role in the promotion and progression of many human cancers including breast cancer. We have recently showed the implication of polymorphism (-251)
Autor:
Yurong Ou, Yanling Zhang, Donghong Yu, Bo Zhu, Zenong Cheng, Lei Zhou, Qiong Zhang, Xiang Yong, Xiaoli Wang, Zhaogen Cai
Publikováno v:
BMC Cancer
BACKGROUND: Centrally necrotizing carcinoma of the breast (CNC) represents a newly-identified subset of breast cancer. The clinical and pathological characteristics of this breast cancer subtype are not yet completely understood. METHODS: We assessed